Komori
KYORIN Pharmaceutical (4569) · TargetFirst statedLatest M&A and Subsidiary Changes (2026-09-30): "Restated"

Executing “Vision 110 – Stage 2 –” and FY2029/FY2032 Targets

First written in FY2026. 3 of 5 entries say "Restated". Latest entry: 2026-09-30.

5entries
1years
4from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestated2026-05-12 – 2026-09-302026: 52026
Same theme, other companies
Executing Vision 110’s long-term growth targets through Stage 2 and Stage 3A theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  2. FY2026First statedAnnual report

    「To achieve further medium- to long-term growth, the Group newly formulated the second-phase medium-term management plan, “Vision 110 – Stage 2 – (FY2026–FY2029),” and began initiatives toward its realization in April 2026.」

    Vision 110 Stage 2 was newly formulated and launched for FY2026 through FY2029. Targets for the end of Stage 2 are revenue of at least ¥120 billion, operating profit before R&D expenses of at least ¥17 billion and ROE of at least 5%; Stage 3 targets are revenue of at least ¥160 billion, operating profit before R&D expenses of at least ¥20 billion and ROE of at least 8%.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for KYORIN Pharmaceutical yet. It last moved in the M&A and Subsidiary Changes of 2026-09-30: "Restated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Executing “Vision 110 – Stage 2 –” and FY2029/FY2032 Targets | KYORIN Pharmaceutical Co.,Ltd. (4569) | Komori